FDA — authorised 18 October 1978
- Status: approved
🇺🇸 Mefoxin In Sodium Chloride 0.9% In Plastic Container in United States
FDA authorised Mefoxin In Sodium Chloride 0.9% In Plastic Container on 18 October 1978
Marketing authorisations
FDA — authorised 27 February 1997
- Application: NDA050581
- Marketing authorisation holder: MERCK
- Local brand name: MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 3 July 2000
- Application: ANDA065012
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: CEFOXITIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 3 July 2000
- Application: ANDA065011
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: CEFOXITIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 September 2000
- Application: ANDA065051
- Marketing authorisation holder: HIKMA
- Local brand name: CEFOXITIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 September 2000
- Application: ANDA065050
- Marketing authorisation holder: HIKMA
- Local brand name: CEFOXITIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 January 2006
- Application: ANDA065313
- Marketing authorisation holder: HOSPIRA INC
- Local brand name: CEFOXITIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 13 February 2006
- Application: ANDA065312
- Marketing authorisation holder: HOSPIRA INC
- Local brand name: CEFOXITIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 12 June 2009
- Application: ANDA065414
- Marketing authorisation holder: ACS DOBFAR
- Local brand name: CEFOXITIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 4 February 2010
- Application: NDA065214
- Marketing authorisation holder: B BRAUN
- Indication: Labeling
- Status: approved
FDA — authorised 26 February 2010
- Application: ANDA065239
- Marketing authorisation holder: HIKMA FARMACEUTICA
- Local brand name: CEFOXITIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 12 March 2010
- Application: ANDA065238
- Marketing authorisation holder: HIKMA FARMACEUTICA
- Local brand name: CEFOXITIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 19 May 2010
- Application: ANDA065415
- Marketing authorisation holder: ACS DOBFAR
- Local brand name: CEFOXITIN
- Indication: INJECTABLE — INJECTION
- Status: approved
Mefoxin In Sodium Chloride 0.9% In Plastic Container in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is Mefoxin In Sodium Chloride 0.9% In Plastic Container approved in United States?
Yes. FDA authorised it on 18 October 1978; FDA authorised it on 27 February 1997; FDA authorised it on 3 July 2000.
Who is the marketing authorisation holder for Mefoxin In Sodium Chloride 0.9% In Plastic Container in United States?
Marketing authorisation holder not available in our data.